Go Pro
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$21.05
-0.7%		$21.20
$16.52
▼
$25.15
$1.53B0.33663,818 shs1.25 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$56.47
+1.1%		$53.43
$26.76
▼
$59.30
$8.55B1.671.82 million shs1.47 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
-0.71%+2.09%-0.94%-6.40%+8.62%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+1.11%+1.95%+12.36%+6.11%+76.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$21.05
-0.7%		$21.20
$16.52
▼
$25.15
$1.53B0.33663,818 shs1.25 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$56.47
+1.1%		$53.43
$26.76
▼
$59.30
$8.55B1.671.82 million shs1.47 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
-0.71%+2.09%-0.94%-6.40%+8.62%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+1.11%+1.95%+12.36%+6.11%+76.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innoviva, Inc. stock logo
INVA
Innoviva
2.50
Moderate Buy$34.7565.08% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.33
Hold$63.0011.56% Upside

Current Analyst Ratings Breakdown

Latest INVA and TGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
9/7/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
9/1/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$78.00
8/31/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/11/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Hold (C+)
8/7/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$36.00 ➝ $34.00
8/7/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$65.00 ➝ $72.00
8/4/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$78.00
7/31/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/29/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
7/27/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $86.00
(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innoviva, Inc. stock logo
INVA
Innoviva
$440.00M3.46$5.00 per share4.21$15.71 per share1.34
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$616.29M14.03$2.83 per share19.93$4.08 per share13.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$4.105.139.84N/A81.19%28.03%20.19%11/4/2026 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$447.18M$2.7420.6121.312.3955.22%73.49%34.14%11/2/2026 (Estimated)

Latest INVA and TGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.3057$0.05-$0.2557$0.05$229.77 million$240.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innoviva, Inc. stock logo
INVA
Innoviva
0.21
16.01
15.18
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.23
4.27
3.72

Institutional Ownership

CompanyInstitutional Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
8.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
15972.25 million70.79 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
399153.07 million139.49 millionOptionable

Recent News About These Companies

TG Therapeutics (NASDAQ:TGTX) Trading 8.3% Higher - Here's Why
September 16 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tg-therapeutics-nasdaq-tgtx-trading-83-higher-heres-why-2026-09-16/
TG Therapeutics (NASDAQ:TGTX) Director Laurence Charney Sells 5,000 Shares
September 15 at 4:53 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025432
TG Therapeutics (NASDAQ:TGTX) Director Sells 5,000 Shares
September 15 at 4:22 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tgtx-insider-buying-and-selling-2026-09-15/
TG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP Ltd
September 15 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-shares-sold-by-winton-group-ltd-2026-09-15/
California State Teachers Retirement System Has $9.37 Million Stock Position in TG Therapeutics, Inc. $TGTX
September 15 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-acquires-9198333-shares-of-tg-therapeutics-inc-tgtx-2026-09-15/
TG Therapeutics (NASDAQ:TGTX) Director Sells $274,800.00 in Stock
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-tg-therapeutics-nasdaq-tgtx-director-sells-27480000-in-stock-2026-09-14/
Hsbc Holdings PLC Has $884,000 Holdings in TG Therapeutics, Inc. $TGTX
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-has-884000-holdings-in-tg-therapeutics-inc-tgtx-2026-09-14/
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $2.17 Million in TG Therapeutics, Inc. $TGTX
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-invests-217-million-in-tg-therapeutics-inc-tgtx-2026-09-11/
TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026  |  quiverquant.comQ
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359392/8790/en/tg-therapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html
TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Strong Sell" at Zacks Research
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tg-therapeutics-nasdaq-tgtx-rating-lowered-to-strong-sell-at-zacks-research-2026-09-09/
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Hold" by Analysts
September 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31008034
Wellington Management Group LLP Increases Stock Position in TG Therapeutics, Inc. $TGTX
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-increases-stock-position-in-tg-therapeutics-inc-tgtx-2026-09-06/
AXQ Capital LP Takes Position in TG Therapeutics, Inc. $TGTX
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-axq-capital-lp-takes-position-in-tg-therapeutics-inc-tgtx-2026-09-06/
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355791/8790/en/tg-therapeutics-to-participate-in-the-cantor-global-healthcare-conference.html
Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-purchases-shares-of-39081-tg-therapeutics-inc-tgtx-2026-09-03/
IBD stock of the day, TG Therapeutics, eyes breakout after topping early buy point
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/ibd-stock-of-the-day-tg-therapeutics-eyes-breakout-after-topping-early-buy-point/ar-AA2bqmLM
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
September 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983861/tg-therapeutics-tgtx-up-15-1-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2983861
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-tg-therapeutics-inc-nasdaq-tgtx-receives-consensus-rating-of-hold-from-analysts-2026-09-02/
TGTX Stock Bounces Back as Analyst Downplays Threat from Novartis
September 1, 2026  |  profitconfidential.comP
TGTX stock pares opening losses after analyst dismisses competition from Novartis
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tgtx-stock-pares-opening-losses-after-analyst-dismisses-competition-from-novartis/ar-AA2bmHU0

New MarketBeat Followers Over Time

Media Sentiment Over Time

Innoviva stock logo

Innoviva NASDAQ:INVA

$21.05 -0.15 (-0.71%)
Closing price 09/17/2026 04:00 PM Eastern
Extended Trading
$21.04 0.00 (-0.02%)
As of 04:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$56.47 +0.62 (+1.11%)
Closing price 09/17/2026 04:00 PM Eastern
Extended Trading
$56.85 +0.38 (+0.67%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas